Greenway Customer ARcare Earns HIMSS Analytics’ Top Honor for Achieving Paperless Care

CARROLLTON, Ga.--Greenway Health customer ARcare has received the coveted Stage 7 Ambulatory Award, HIMSS Analytics’ top recognition of providers that leverage electronic health record (EHR) technology to deliver effective and efficient, paperless care. The award extends to 37 ARcare clinics throughout Arkansas and Kentucky, all of which rely on Greenway for paperless charting and order entry. ARcare is the first federally qualified health center (FQHC) in the U.S. to receive the Stage 7 Ambulatory Award, and one of only two ambulatory practices not connected with a hospital.

“Our ARcare team and indeed all of Greenway Health are honored to be associated with this stellar accomplishment.”

HIMSS Analytics developed the Ambulatory EMR Adoption Model (A-EMRAM) in 2011 to track EMR progress in ambulatory settings, designating Stage 7 as the highest level of achievement in creating and utilizing an advanced electronic patient record environment. During first-quarter 2014, only 4.5 percent of the more than 24,000 U.S. ambulatory clinics have achieved Stage 7 Ambulatory recognition.

“The Greenway team has always really understood our business model, and that’s been key to our ability to eliminate paper,” said Greg Wolverton, ARcare chief information officer. “We’re very agile, and they’ve been able to work with us to support tremendous progress on an accelerated timeline.”

ARcare is a private, non-profit organization providing affordable primary medical and dental care to the residents in rural Arkansas and western Kentucky through a network of primary care clinics, dental clinics, pharmacies and wellness centers. In Kentucky, it operates as KentuckyCare. ARcare has achieved 99-percent computerized physician order entry and 100-percent documentation in structured forms throughout its care network, thanks in part to the organization’s requirement that all of its physicians undergo three weeks of EHR training in both proficiency and use expectations.

“Greenway applauds ARcare’s tremendous achievements in the electronification of patient health information to better coordinate and improve care across its provider network,” said Greenway® CEO Tee Green. “Our ARcare team and indeed all of Greenway Health are honored to be associated with this stellar accomplishment.”

ARcare will be recognized at the Healthcare Information and Management Systems Society (HIMSS) Annual Conference & Exhibition on April 12-16, 2015, in Chicago, IL.

For more information about ARcare and the benefits it receives from its Greenway solutions and relationship, see the feature article on the Greenway Health website.

About Greenway Health

Greenway Health delivers the clinical, financial and administrative solutions healthcare providers need to effectively manage the delivery of quality care and improve health outcomes for patient populations. For over 30 years, Greenway has offered smarter solutions that help providers succeed in an evolving value-based healthcare system. Greenway’s clinically driven revenue cycle management services and comprehensive suite of interoperable solutions improve financial performance and automate clinical and administrative workflows, so medical providers can spend time on patients instead of paperwork. For more information, visit www.greenwayhealth.com or call (866) 242-3805. Follow Greenway on Facebook, Twitter and LinkedIn.

Cited marks are trademarks or registered trademarks of Greenway Health, LLC or its affiliates. Other product or company names are the property of their respective owners.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.